GlobeNewswire·Nov 17, 2025, 8:00 AM ET

Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference

Grace Therapeutics, Inc. (NASDAQ: GRCE) CEO Prashant Kohli will present at the Craig-Hallum 16th Annual Alpha Select Conference on Tuesday, November 18, 2025, in New York, NY.
The Alpha Select Conference is an invitation-only event featuring sub-$500M market cap companies with growth potential selected by the Craig-Hallum research team.
Meetings with Mr. Kohli can be requested through a Craig-Hallum representative.
Aneurysmal subarachnoid hemorrhage (aSAH) is a stroke type accounting for approximately 5% of all strokes, affecting an estimated 42,500 U.S. hospital-treated patients annually.
GTx-104 is a clinical-stage, novel injectable formulation of nimodipine designed for IV infusion to treat aSAH.
GTx-104 utilizes unique nanoparticle technology to enable aqueous formulation of insoluble nimodipine for standard peripheral IV infusion.
IV delivery of GTx-104 aims to eliminate the need for nasogastric tubes, reduce food effects, minimize drug-to-drug interactions, prevent dosing errors, & better manage hypotension.
GTx-104 has been administered to over 200 patients & healthy volunteers, demonstrating good tolerance & significantly lower pharmacokinetic variability compared to oral nimodipine.
Grace Therapeutics is a late-stage biopharma company focusing on rare & orphan diseases, with lead assets holding Orphan Drug Designation & over 40 granted & pending patents.